Clinical Trial Update: Sublingual Dexmedetomidine for Treating Opioid Withdrawal [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update shows Phase 1/2 evaluation of sublingual dexmedetomidine for opioid withdrawal. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder
• Opioid Withdrawal

Drugs mentioned

• Dexmedetomidine (sublingual) (dexmedetomidine)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Opioid Use Disorder, Opioid Withdrawal | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING